

## Osteogenesis imperfecta: Klinik, Diagnose und Management vom Kindes- bis ins Erwachsenenalter

## Ostéogénèse imparfaite: manifestations cliniques, diagnostic et prise en charge de l'enfance à l'âge adulte

### Literatur / Références

1. Marini JC ed. Nelson textbook of pediatrics Saunders, Philadelphia; 2004:2336-2338
2. Martin E, Shapiro JR. Osteogenesis imperfecta: epidemiology and pathophysiology. *Curr Osteoporos Rep* 2007;5:91-97
3. Phillipi CA, Remington T, Steiner RD. Bisphosphonate therapy for osteogenesis imperfecta. *Cochrane Database Syst Rev* 2008:CD005088
4. Barbosa-Buck CO, Orioli IM, da Graca Dutra M, Lopez-Camelo J, Castilla EE, Cavalcanti DP. Clinical epidemiology of skeletal dysplasias in South America. *American journal of medical genetics* 2012;158A:1038-1045
5. Silience DO, Rimoin DL. Classification of osteogenesis imperfect. *Lancet* 1978;1:1041-1042
6. Silience DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. *Journal of medical genetics* 1979;16:101-116
7. Rohrbach M, Giunta C. Recessive osteogenesis imperfecta: clinical, radiological, and molecular findings. *Am J Med Genet C Semin Med Genet* 2012;160C:175-189
8. Semler O, Garbes L, Keupp K, Swan D, Zimmermann K, Becker J, et al. A mutation in the 5'-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus. *American journal of human genetics* 2012;91:349-357
9. Homan EP, Rauch F, Grafe I, Lietman C, Doll JA, Dawson B, et al. Mutations in SERPINF1 cause osteogenesis imperfecta type VI. *J Bone Miner Res* 2011;26:2798-2803
10. Raghunath M, Steinmann B, Delozier-Blanchet C, Extermann P, Superti-Furga A. Prenatal diagnosis of collagen disorders by direct biochemical analysis of chorionic villus biopsies. *Pediatr Res* 1994;36:441-448
11. Wallis GA, Starman BJ, Zinn AB, Byers PH. Variable expression of osteogenesis imperfecta in a nuclear family is explained by somatic mosaicism for a lethal point mutation in the alpha 1(I) gene (COL1A1) of type I collagen in a parent. *American journal of human genetics* 1990;46:1034-1040
12. Pyott SM, Pepin MG, Schwarze U, Yang K, Smith G, Byers PH. Recurrence of perinatal lethal osteogenesis imperfecta in sibships: parsing the risk between parental mosaicism for dominant mutations and autosomal recessive inheritance. *Genet Med* 2011;13:125-130
13. Krakow D, Alanay Y, Rimoin LP, Lin V, Wilcox WR, Lachman RS, et al. Evaluation of prenatal-onset osteochondrodysplasias by ultrasonography: a retrospective and prospective analysis. *American journal of medical genetics* 2008;146A:1917-1924
14. Pryde PG, Zelop C, Pauli RM. Prenatal diagnosis of isolated femoral bent bone skeletal dysplasia: problems in differential diagnosis and genetic counseling. *American journal of medical genetics* 2003;117A:203-206
15. Cubert R, Cheng EY, Mack S, Pepin MG, Byers PH. Osteogenesis imperfecta: mode of delivery and neonatal outcome. *Obstetrics and gynecology* 2001;97:66-69
16. Parasuraman R, Taylor MJ, Liversedge H, Gilg J. Pregnancy management in type III maternal osteogenesis imperfecta. *J Obstet Gynaecol* 2007;27:619-621
17. Pabinger C, Heu C, Frohner A, Dimai HP. Pregnancy- and lactation-associated transient osteoporosis of both hips in a 32 year old patient with osteogenesis imperfecta. *Bone* 2012;51:142-144
18. Levy S, Fayed I, Taguchi N, Han JY, Aiello J, Matsui D, et al. Pregnancy outcome following in utero exposure to bisphosphonates. *Bone* 2009;44:428-430
19. Christodoulou S, Freemont AJ, McVey R, Vause S. Prospective comparative case study of uterine collagen in a woman with osteogenesis imperfecta type 1 who had previously ruptured her uterus. *J Obstet Gynaecol* 2007;27:738-739
20. Di Lieto A, Pollio F, De Falco M, Iannotti F, Mascolo M, Somma P, et al. Collagen content and growth factor immun-expression in uterine lower segment of type IA osteogenesis imperfecta: Relationship with recurrent uterine rupture in pregnancy. *American journal of obstetrics and gynecology* 2003;189:594-600
21. Bishop N. Characterising and treating osteogenesis imperfecta. *Early human development* 2010;86:743-746
22. Esposito P, Plotkin H. Surgical treatment of osteogenesis imperfecta: current concepts. *Current opinion in pediatrics* 2008;20:52-57
23. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. *The New England journal of medicine* 1998;339:947-952
24. Rauch F, Glorieux FH. Osteogenesis imperfecta. *Lancet* 2004;363:1377-1385

25. Roldan EJ, Pasqualini T, Plantalech L. Bisphosphonates in children with osteogenesis imperfecta may improve bone mineralization but not bone strength. Report of two patients. *J Pediatr Endocrinol Metab* 1999;12:555-559
26. Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. *The Journal of clinical investigation* 2002;110:1293-1299
27. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. *The Journal of clinical endocrinology and metabolism* 2003;88:986-992
28. Rauch F, Plotkin H, Zeitlin L, Glorieux FH. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. *J Bone Miner Res* 2003;18:610-614
29. Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tato L, et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. *J Bone Miner Res* 2005;20:758-763
30. Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. *J Bone Miner Res* 2005;20:977-986
31. McKiernan FE. Musculoskeletal manifestations of mild osteogenesis imperfecta in the adult. *Osteoporos Int* 2005;16:1698-1702
32. Balkefors V, Mattsson E, Pernow Y, Saaf M. Functioning and Quality of Life in Adults with Mild-to-Moderate Osteogenesis Imperfecta. *Physiother Res Int* 2012
33. Paterson CR, McAllion S, Stellman JL. Osteogenesis imperfecta after the menopause. *The New England journal of medicine* 1984;310:1694-1696
34. Primorac D, Rowe DW, Mottes M, Barisic I, Anticevic D, Mirandola S, et al. Osteogenesis imperfecta at the beginning of bone and joint decade. *Croatian medical journal* 2001;42:393-415
35. Wekre LL, Eriksen EF, Falch JA. Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta. *Archives of osteoporosis* 2011;6:31-38
36. Folkestad L, Hald JD, Hansen S, Gram J, Langdahl B, Abrahamsen B, et al. Bone geometry, density, and microarchitecture in the distal radius and tibia in adults with osteogenesis imperfecta type I assessed by high-resolution pQCT. *J Bone Miner Res* 2012;27:1405-1412
37. Braga V, Gatti D, Rossini M, Colapietro F, Battaglia E, Viapiana O, et al. Bone turnover markers in patients with osteogenesis imperfecta. *Bone* 2004;34:1013-1016
38. Cundy T, Horne A, Bolland M, Gamble G, Davidson J. Bone formation markers in adults with mild osteogenesis imperfecta. *Clinical chemistry* 2007;53:1109-1114
39. Garnero P, Schott AM, Prockop D, Chevrel G. Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations. *Bone* 2009;44:461-466
40. Bradbury LA, Barlow S, Geoghegan F, Hannon RA, Stuckey SL, Wass JA, et al. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. *Osteoporos Int* 2012;23:285-294
41. Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M, et al. Intravenous neridronate in adults with osteogenesis imperfecta. *J Bone Miner Res* 2003;18:126-130
42. Chevrel G, Schott AM, Fontanges E, Charrin JE, Lina-Granade G, Duboeuf F, et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. *J Bone Miner Res* 2006;21:300-306
43. Shapiro JR, Thompson CB, Wu Y, Nunes M, Gillen C. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta. *Calcified tissue international* 2010;87:120-129